GlaxoSmithKline plc (GSK) recently announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99M) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK?s R&D organisation.
Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. This novel antibody discovery technology, named NG-XMTTM, harnesses the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an immunized animal.
Scientists at ETH Zurich, along with AB SCIEX, a global leader in life science analytical technologies, have completed their development of MS/MSALL with SWATH(TM) Acquisition, a groundbreaking mass spectrometry-based proteomics technique that quantifies nearly all peptides and proteins in a sample from a single analysis.
